[go: up one dir, main page]

SG11201703609UA - Methods and formulations for treating vascular eye diseases - Google Patents

Methods and formulations for treating vascular eye diseases

Info

Publication number
SG11201703609UA
SG11201703609UA SG11201703609UA SG11201703609UA SG11201703609UA SG 11201703609U A SG11201703609U A SG 11201703609UA SG 11201703609U A SG11201703609U A SG 11201703609UA SG 11201703609U A SG11201703609U A SG 11201703609UA SG 11201703609U A SG11201703609U A SG 11201703609UA
Authority
SG
Singapore
Prior art keywords
formulations
methods
eye diseases
treating vascular
vascular eye
Prior art date
Application number
SG11201703609UA
Inventor
Robert L Vitti
Kristine A Erickson
Karen W Chu
Stanley J Wiegand
Jingtai Cao
Ivan B Lobov
Saurabh Wadhwa
Kenneth S Graham
Daniel Dix
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201703609UA publication Critical patent/SG11201703609UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
SG11201703609UA 2014-11-25 2015-11-19 Methods and formulations for treating vascular eye diseases SG11201703609UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462084003P 2014-11-25 2014-11-25
US201562147232P 2015-04-14 2015-04-14
US14/943,490 US20160144025A1 (en) 2014-11-25 2015-11-17 Methods and formulations for treating vascular eye diseases
PCT/US2015/061543 WO2016085750A1 (en) 2014-11-25 2015-11-19 Methods and formulations for treating vascular eye diseases

Publications (1)

Publication Number Publication Date
SG11201703609UA true SG11201703609UA (en) 2017-06-29

Family

ID=56009149

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703609UA SG11201703609UA (en) 2014-11-25 2015-11-19 Methods and formulations for treating vascular eye diseases

Country Status (18)

Country Link
US (3) US20160144025A1 (en)
EP (1) EP3224278A4 (en)
JP (2) JP2017536414A (en)
KR (1) KR20170087950A (en)
CN (1) CN107001457A (en)
AU (1) AU2015353838A1 (en)
BR (1) BR112017009807A2 (en)
CA (1) CA2968522A1 (en)
CL (1) CL2017001188A1 (en)
CO (1) CO2017004715A2 (en)
EA (1) EA201791168A1 (en)
IL (1) IL252159B (en)
MA (2) MA41028A (en)
MX (1) MX2017006129A (en)
PE (1) PE20170900A1 (en)
PH (1) PH12017500834A1 (en)
SG (1) SG11201703609UA (en)
WO (1) WO2016085750A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633574T3 (en) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
PT2944306T (en) 2006-06-16 2021-02-15 Regeneron Pharma Vegf antagonist formulations suitable for intravitreal administration
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN105412094A (en) 2009-07-06 2016-03-23 爱尔皮奥治疗有限公司 Compounds, Compositions, And Methods For Preventing Metastasis Of Cancer Cells
JO3182B1 (en) * 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
HK1218071A1 (en) 2013-02-21 2017-02-03 Rsem, Limited Partnership Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US11104730B2 (en) 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI738632B (en) 2014-11-07 2021-09-11 瑞士商諾華公司 Stable protein solution formulation containing high concentration of an anti-vegf antibody
JP6726734B2 (en) * 2015-03-26 2020-07-22 アイコー，エルエルシー System for image analysis
ES2981607T3 (en) 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Tie-2 activators for use in the treatment of intraocular pressure
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
AU2017299581B2 (en) 2016-07-20 2024-05-23 EyePoint Pharmaceuticals, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
US20200056186A1 (en) 2016-09-22 2020-02-20 Rsem, Limited Partnership Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
EP3527225A4 (en) * 2016-10-12 2020-06-10 Daiichi Sankyo Company, Limited COMPOSITION CONTAINING ANTI-ROBO4 ANTIBODY AND OTHER AGENT
JP7161494B2 (en) * 2017-05-06 2022-10-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods of treating eye diseases with APLNR antagonists and VEGF inhibitors
KR102798461B1 (en) * 2017-08-18 2025-04-18 리제너론 파마슈티칼스 인코포레이티드 Image capillary isoelectric focusing to analyze protein variants in a sample matrix
EP3716992B1 (en) * 2017-11-30 2022-08-10 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CA3189025A1 (en) * 2017-12-22 2019-06-27 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
SG11202007130RA (en) 2018-01-26 2020-08-28 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
CN119733046A (en) * 2018-02-06 2025-04-01 豪夫迈·罗氏有限公司 Treatment of eye diseases
CN112203679A (en) 2018-03-02 2021-01-08 科达制药股份有限公司 IL-6 antibodies and fusion constructs and conjugates thereof
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CN108671229B (en) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 Pharmaceutical composition preparation of recombinant human vascular endothelial growth factor receptor-antibody fusion protein
BR112020022610A2 (en) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. high concentration vegf receptor fusion protein containing formulations
JP7249060B2 (en) * 2018-08-17 2023-03-30 トリカン・バイオテクノロジー・カンパニー・リミテッド Antiangiogenic fusion proteins and uses thereof
CN109598628B (en) * 2018-11-30 2022-09-20 平安医疗健康管理股份有限公司 Method, device and equipment for identifying medical insurance fraud behaviors and readable storage medium
MX2021007393A (en) 2018-12-18 2021-09-23 Novartis Ag PROTEIN SOLUTION FORMULATION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY.
KR102735988B1 (en) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 therapeutic antibody preparations
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
CN110423281B (en) * 2019-07-31 2021-04-30 成都金唯科生物科技有限公司 Fusion protein, viral vector and drug for treating age-related macular degeneration
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
CN113493519B (en) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 Fusion protein with remarkably prolonged half-life for treating ocular angiogenesis diseases
JP2023523246A (en) * 2020-04-29 2023-06-02 ノバルティス アーゲー Computer-implemented system and method for assessing disease or condition activity level in a patient's eye
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
CA3190173A1 (en) * 2020-06-22 2021-12-30 Innovent Biologics (Suzhou) Co., Ltd. Anti-ang-2 antibody and use thereof
US20230270670A1 (en) * 2020-07-24 2023-08-31 Pangen Biotech Inc. Ophthalmic liquid composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
AR059066A1 (en) * 2006-01-27 2008-03-12 Amgen Inc COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
PT2944306T (en) * 2006-06-16 2021-02-15 Regeneron Pharma Vegf antagonist formulations suitable for intravitreal administration
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
AR076796A1 (en) * 2009-05-28 2011-07-06 Glaxo Group Ltd PROTEINS OF UNION TO THE ANTIGEN. PHARMACEUTICAL COMPOSITION USE. PROCESS.
JO3182B1 (en) * 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) * 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
TWI426920B (en) * 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-VEGF/anti-ANG-2 antibody
BR112013017752A8 (en) * 2011-01-13 2018-01-09 Regeneron Pharma use of a vegf antagonist and pharmaceutical formulation
MY164611A (en) * 2012-01-23 2018-01-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
PE20150361A1 (en) * 2012-07-13 2015-03-14 Roche Glycart Ag ANTI-VEGF / ANTI-ANG-2 BISPECIFIC ANTIBODIES AND THEIR USE IN THE TREATMENT OF EYE VASCULAR DISEASES
CA2893767C (en) * 2012-12-05 2022-11-08 Novartis Ag Compositions and methods for antibodies targeting epo
JO3405B1 (en) * 2013-01-09 2019-10-20 Regeneron Pharma ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
RU2676303C2 (en) * 2013-07-11 2018-12-27 Новартис Аг Use of vegf antagonist for treating retinopathy of prematurity
US9914769B2 (en) * 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
DE112014005975T5 (en) * 2013-12-17 2016-09-15 Kymab Limited Human goals

Also Published As

Publication number Publication date
CL2017001188A1 (en) 2017-11-24
US20170080086A1 (en) 2017-03-23
MA40306A1 (en) 2019-03-29
CO2017004715A2 (en) 2017-09-20
MX2017006129A (en) 2018-04-10
CA2968522A1 (en) 2016-06-02
US20160144025A1 (en) 2016-05-26
JP2021046431A (en) 2021-03-25
CN107001457A (en) 2017-08-01
WO2016085750A1 (en) 2016-06-02
MA41028A (en) 2017-10-03
EP3224278A4 (en) 2018-07-11
PH12017500834A1 (en) 2017-10-30
AU2015353838A1 (en) 2017-06-08
EA201791168A1 (en) 2017-09-29
PE20170900A1 (en) 2017-07-12
IL252159B (en) 2021-03-25
BR112017009807A2 (en) 2018-02-27
EP3224278A1 (en) 2017-10-04
US20190117767A1 (en) 2019-04-25
KR20170087950A (en) 2017-07-31
US11071780B2 (en) 2021-07-27
JP2017536414A (en) 2017-12-07
IL252159A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
IL252159B (en) Methods and formulations for treating vascular eye diseases
IL283561B (en) Methods for treating ocular diseases
IL265590B (en) Keratin treatment formulations and methods
IL246791A0 (en) Compositions and methods for treating ocular diseases
IL253244A0 (en) Methods of treating retinal diseases
SG11201706755SA (en) Methods and compositions for treating genetic eye diseases
IL248732B (en) Compounds for treating ophthalmic diseases and disorders
IL252819A0 (en) Hypochlorous acid formulations and methods for treating skin conditions
EP3030275A4 (en) Method of treating peripheral artery diseases in lower limbs
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3030276A4 (en) Method of treating peripheral artery diseases in lower limbs
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
SG11201704829QA (en) Methods and compositions for treating brain diseases
EP3030274A4 (en) Method of treating peripheral artery diseases in lower limbs
IL252904A0 (en) Methods and agents for treating disease
IL253847A0 (en) Methods of treating diseases
EP3265103A4 (en) Compositions and methods for treating ocular diseases
IL252707B (en) Compositions and methods for treating diseases and conditions
SG11202005278PA (en) Compounds for treating eye diseases and methods thereof
ZA201802201B (en) Novel formulation and treatment methods
EP3188744A4 (en) Methods for treatment and prevention of vascular disease
IL246608A0 (en) Compositions and methods for treating heart disease
HK1235307A1 (en) Methods for treating ocular diseases
AU2014903547A0 (en) Method for treatment and prevention of vascular disease